Table 2 Presenting features of the... | American Society of Hematology

Table 2

Presenting features of the randomly assigned patients with B-precursor acute lymphoblastic leukemia

	PO MTX, n	IV MTX, n	P	SDI, n	DDI, n	P
Age
< 2 y	85	82		79	88	.76
2-5 y	733	720	.55	726	727
6-9 y	218	240		232	226
Sex
F	475	454	.32	451	478	.29
M	561	588		586	563
Ethnicity
White	705	719		721	703
Black	40	36		36	40
Hispanic	196	203	.99	194	205	.26
Asian	28	27		21	34
Other	67	57		65	59
WBC count
< 20 × 10⁹/L	856	867	.92	871	852	.14
> 20 × 10⁹/L	176	175		162	189
CNS status
CNS-1	799	831		809	829
CNS-2	32	35	.08	32	35	.87
TLP⁺	25	12		17	20
Cytology
ETV6/RUNX1*	176	182	.95	182	176	.58
Trisomy 4 and 10†	117	133	.30	132	118	.47
Down syndrome	44	31	.15	42	33	.33
BM day 7
Ml	495	470		491	474
M2	298	319	.45	300	317	.45
M3	216	227		218	225
BM day 14
Ml	532	579	.45	556	555	.06
M2	18	18		10	22

	PO MTX, n	IV MTX, n	P	SDI, n	DDI, n	P
Age
< 2 y	85	82		79	88	.76
2-5 y	733	720	.55	726	727
6-9 y	218	240		232	226
Sex
F	475	454	.32	451	478	.29
M	561	588		586	563
Ethnicity
White	705	719		721	703
Black	40	36		36	40
Hispanic	196	203	.99	194	205	.26
Asian	28	27		21	34
Other	67	57		65	59
WBC count
< 20 × 10⁹/L	856	867	.92	871	852	.14
> 20 × 10⁹/L	176	175		162	189
CNS status
CNS-1	799	831		809	829
CNS-2	32	35	.08	32	35	.87
TLP⁺	25	12		17	20
Cytology
ETV6/RUNX1*	176	182	.95	182	176	.58
Trisomy 4 and 10†	117	133	.30	132	118	.47
Down syndrome	44	31	.15	42	33	.33
BM day 7
Ml	495	470		491	474
M2	298	319	.45	300	317	.45
M3	216	227		218	225
BM day 14
Ml	532	579	.45	556	555	.06
M2	18	18		10	22

PO indicates oral; MTX, methotrexate; SDI, single delayed intensification phase; DDI, double delayed intensification phase; WBC, white blood cell; and TLP⁺, traumatic lumbar punctures with lymphoblasts present in the spinal fluid.

Patients (n = 1041) were analyzed for the presence of ETV6/RUNX1 transcript.

†

Patients (n = 1330) were evaluated for the presence of trisomies 4 and 10.

View Large

This Feature Is Available To Subscribers Only